Clinical Trials Logo

Filter by:
NCT ID: NCT03453281 Completed - Clinical trials for Diabetic Retinopathy

Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection

Start date: October 10, 2017
Phase: Phase 4
Study type: Interventional

This is a one month pre post intervention study. Subjects with diabetic macular edema were given intravitreal anti VEGF (Aflibercept) injection. Central retinal thickness, macular electrophysiology, and visual acuity were observed one week and one month after injection was given to the eye to describe early anatomical, physiological, and clinical changes. We hypothesized that changes to these outcomes can be found and documented.

NCT ID: NCT03434197 Completed - Clinical trials for Osteoarthritis Knee Pain

Safety and Efficacy of SFPP in Knee Osteoarthritis

Start date: February 5, 2018
Phase: Phase 3
Study type: Interventional

The objectives of this study are to demonstrate the non-inferiority of esflurbiprofen plaster (SFPP) 40 mg applied for 2 weeks to diclofenac gel, the comparator, in terms of efficacy in patients with knee osteoarthritis (OA) and to examine the safety of SFPP.

NCT ID: NCT03431649 Completed - Clinical trials for Pediatric Pulmonary Hypertension

Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children

Start date: April 1, 2017
Phase: Phase 4
Study type: Interventional

To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt. analyze the efficacy and side effects.

NCT ID: NCT03422575 Completed - Healthy Clinical Trials

Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets

Start date: December 2015
Phase: N/A
Study type: Interventional

The present study was a randomized, open-label, two-period, two-sequence, cross-over study, conducted to find out whether the etoricoxib 120 mg film-coated tablet produced by PT Dexa Medica (test drug) was bioequivalent to the reference drug (Arcoxia® Film-Coated Tablet 120 mg, PT. Schering-Plough Indonesia Tbk), under fasting condition with a fourteen days wash-out period, involving 26 healthy adult male and female subjects.

NCT ID: NCT03383653 Completed - Healthy Clinical Trials

Safety Profile Following Td Vaccination in Indonesian Pregnant Woman

Start date: August 29, 2017
Phase: N/A
Study type: Observational [Patient Registry]

To assess any serious systemic reaction within 30 minutes after Td immunization in pregnant woman

NCT ID: NCT03366454 Completed - Pneumonia Clinical Trials

Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests (RDTs), Biomarkers and SoCs for the Etiology Diagnoses of Pneumonia in Pediatric Patients to Improve Clinical Management in Indonesia.

PEER-PePPes
Start date: July 4, 2017
Phase:
Study type: Observational

Participants who meet the inclusion and exclusion criteria will be enrolled and then having a daily follow up for maximum of 13 days' hospitalization. Next follow up will be taken time at day 14th after hospitalization date, either on ward or policlinic. The participations will be ended by day 30th after hospitalization date when the called follow up is done by investigator.

NCT ID: NCT03358524 Completed - Oxidative Stress Clinical Trials

Effects of Vitamin E Supplementation on Free Radicals and Fat Level of Obese Adolescence in Jakarta, Indonesia

Start date: September 28, 2017
Phase: Phase 4
Study type: Interventional

This study evaluate supplementation of vitamin E (alpha-tocopherol) in obese adolescent. Half of the patient will receive vitamin E and the other half received placebo

NCT ID: NCT03354299 Completed - Malnutrition Clinical Trials

Effect of Coconut Milk Supplementation to Improve Nutritional Status in Cirrhosis Patient

Start date: June 2014
Phase: N/A
Study type: Interventional

Liver cirrhosis still becomes a major issue in Indonesia. Malnutrition has been observed in liver cirrhosis patients as it deteriorates liver function and cirrhosis itself. Malnutrition in liver cirrhosis can increase morbidity and mortality rates. Patients with liver cirrhosis have increased energy expenditure and endogenous fat oxidation reaction which is used as the basic energy sources. Energy obtained from fat was accounted for 86% of the total energy sources in this population. Fatty acid is also known to be an efficient energy backup for hepatocytes and other cells because it generates higher adenosine triphosphate (ATP) than other sources. Supplementary diet for patients with liver cirrhosis is considered beneficial for preventing hypercatabolism. To fulfill their nutritional needs, patients with liver cirrhosis is advised to take an extra food, such as a late night snack (LNS) with a total carbohydrate of around 50 g (equivalent to 200 kkal). Considering that most of the energy source in patients with liver cirrhosis came from fat, so the additional sources of energy having a high fat content were considered to be potentially highly beneficial to address the patients' nutritional status, as well as to reduce the risk of hyperglycemia after a meal and hypoglycemia after a long night fasting period time. Coconut milk contains many saturated fatty acids belonging to the medium chain triacylglycerol (MCT) group. The characteristics of MCT are quite different from long chain triacylglycerol (LCT). MCTs are more easily absorbed than LCTs, and are mostly absorbed in the form of free fatty acids, in both healthy and liver cirrhosis populations. This study wants to investigate the effects of coconut milk supplementation on improving the nutritional status of patients with liver cirrhosis. The patients were divided into 2 groups, groups I received 25 g of sugar plus 50 cc of coconut milk (200 kkal) as late night snacks (LNS); and group II received 50 g of sugar alone (200 kkal) as LNS. Investigators think that the group who received coconut milk supplementation has better nutritional status than the other group.

NCT ID: NCT03352674 Completed - Diabetes Mellitus Clinical Trials

Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

Start date: September 2016
Phase: Phase 2
Study type: Interventional

This is an open-label randomised multicenter clinical study to compare immunogenicity of the drug products Insulin Glargine (Kalbe Farma) and Lantus (Sanofi -Aventis) in type 2 diabetes mellitus patients

NCT ID: NCT03352206 Completed - Clinical trials for Lymphatic Filariases

Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis

Start date: October 18, 2017
Phase:
Study type: Observational

This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities. Parameters measured will include: circulating filarial antigenemia (CFA) assessed with the Filariasis Test Strip (FTS), antifilarial antibodies tested with plasma and microfilaremia (assessed by night blood smears and microscopy).